Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation
Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the...
Saved in:
Published in | CrystEngComm Vol. 23; no. 3; pp. 653 - 662 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cambridge
Royal Society of Chemistry
25.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H
2
O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid (
REG
-
MA
), glutaric acid (
REG
-
GA
) and pimelic acid (
REG
-
PA
) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H
2
O,
REG
-
MA
exhibits comparable dissolution behavior, while
REG
-
GA
and
REG
-
PA
demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that
REG
-
GA
and
REG
-
PA
have great potential to be developed as new, more efficient formulations of REG.
Three cocrystals of regorafenib were synthesized, and two of them demonstrate significantly improved solubility and tabletability without compromising physicochemical stability. |
---|---|
AbstractList | Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H
2
O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid (
REG
–
MA
), glutaric acid (
REG
–
GA
) and pimelic acid (
REG
–
PA
) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H
2
O,
REG
–
MA
exhibits comparable dissolution behavior, while
REG
–
GA
and
REG
–
PA
demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that
REG
–
GA
and
REG
–
PA
have great potential to be developed as new, more efficient formulations of REG. Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H2O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid (REG–MA), glutaric acid (REG–GA) and pimelic acid (REG–PA) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H2O, REG–MA exhibits comparable dissolution behavior, while REG–GA and REG–PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG–GA and REG–PA have great potential to be developed as new, more efficient formulations of REG. Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced hepatocellular carcinoma. REG exists in various crystal forms and its monohydrate form (REG·H 2 O) is selected as the commercial form. However, the clinical efficacy of REG is severely limited by low oral bioavailability due to its poor aqueous solubility. With the intention to expand the solid forms and to improve the aqueous solubility at the same time, three cocrystals of REG with malonic acid ( REG - MA ), glutaric acid ( REG - GA ) and pimelic acid ( REG - PA ) were successfully synthesized by liquid-assisted grinding and/or the slurry methods. The obtained cocrystals were fully characterized by X-ray diffraction analysis, thermal analysis, and Fourier transform infrared and proton nuclear magnetic resonance spectroscopy, and were then subjected to powder dissolution, dynamic vapor sorption, stability and tabletability investigations. As compared to REG·H 2 O, REG - MA exhibits comparable dissolution behavior, while REG - GA and REG - PA demonstrate significantly enhanced apparent solubility and dissolution rates without compromising the hygroscopicity and physicochemical stability of the drug. In addition, the formation of the cocrystals also improves the tabletability of the powdered samples. These results suggest that REG - GA and REG - PA have great potential to be developed as new, more efficient formulations of REG. Three cocrystals of regorafenib were synthesized, and two of them demonstrate significantly improved solubility and tabletability without compromising physicochemical stability. |
Author | Li, Meng-Ting Jia, Jun-Long Dai, Xia-Lin Che, Hao-Jie Chen, Jia-Mei Zhuang, Xiao-Mei Lu, Tong-Bu |
AuthorAffiliation | School of Information Engineering Tianjin Key Laboratory of Drug Targeting and Bioimaging Institute for New Energy Materials and Low Carbon Technologies School of Materials Science and Engineering Tianjin University of Technology Zhongshan Polytechnic School of Chemistry and Chemical Engineering |
AuthorAffiliation_xml | – name: School of Information Engineering – name: School of Chemistry and Chemical Engineering – name: Zhongshan Polytechnic – name: Institute for New Energy Materials and Low Carbon Technologies – name: Tianjin University of Technology – name: School of Materials Science and Engineering – name: Tianjin Key Laboratory of Drug Targeting and Bioimaging |
Author_xml | – sequence: 1 givenname: Jun-Long surname: Jia fullname: Jia, Jun-Long – sequence: 2 givenname: Xia-Lin surname: Dai fullname: Dai, Xia-Lin – sequence: 3 givenname: Hao-Jie surname: Che fullname: Che, Hao-Jie – sequence: 4 givenname: Meng-Ting surname: Li fullname: Li, Meng-Ting – sequence: 5 givenname: Xiao-Mei surname: Zhuang fullname: Zhuang, Xiao-Mei – sequence: 6 givenname: Tong-Bu surname: Lu fullname: Lu, Tong-Bu – sequence: 7 givenname: Jia-Mei surname: Chen fullname: Chen, Jia-Mei |
BookMark | eNptUd1LwzAQDzLBbfriuxDwTaxemrSkvmmdHzDwRZ_LNU1dRm1mkjnrX2-3iYr4dMfx-7j73YgMWttqQg4ZnDHg2XkFSgPjgpU7ZMhEmkYSOB_86vfIyPs5ABOMwZDUuVWu8wEbT21NnX62DmvdmpKuTJjRyih0pX3vGqMoKlP5C-q7Nsy0N_6Uqhk6VEE784HB2JZiW9GFswvtQkf1GzbLzXyf7Na9hT74qmPydDN5zO-i6cPtfX45jVTMeYhiiFGWDAQTSrA4yTBjEqTWVYJY8zTNMiUBVKV4ohnWUPJKoEw4CBHzhPExOd7q9ju8LrUPxdwuXdtbFrGQEGcAco062aKUs947XRcLZ17QdQWDYp1jcQ35ZJPjVQ-GP2Blwuao4NA0_1OOthTn1bf0z2v4J1EggYg |
CitedBy_id | crossref_primary_10_1039_D1CE01674A crossref_primary_10_1016_j_colsurfa_2023_132835 crossref_primary_10_1016_j_drudis_2023_103527 crossref_primary_10_1016_j_heliyon_2024_e29049 crossref_primary_10_3390_pharmaceutics15092174 crossref_primary_10_3390_cryst12101337 crossref_primary_10_2174_1574892817666220913151252 crossref_primary_10_1016_j_jcou_2025_103040 crossref_primary_10_1021_acs_cgd_1c00480 crossref_primary_10_3390_pharmaceutics13060790 crossref_primary_10_1016_j_jddst_2023_105239 crossref_primary_10_3390_molecules28104242 |
Cites_doi | 10.1021/acs.cgd.8b00362 10.1016/0006-291X(62)90292-9 10.1021/acs.molpharmaceut.5b00020 10.1016/j.phrs.2013.11.002 10.1021/mp5004652 10.3390/pharmaceutics12060546 10.1107/S2053229616003727 10.1016/j.molstruc.2008.01.009 10.1016/j.ejps.2015.10.006 10.1021/cg700843s 10.1021/acs.cgd.9b00618 10.1158/1078-0432.CCR-11-1900 10.1016/j.colsurfb.2017.02.006 10.1039/C8CE00341F 10.3390/71200871 10.1134/S0023158407030068 10.1021/acs.cgd.0c00326 10.1023/B:PHAM.0000016272.81390.b4 10.1021/jm070245n 10.1016/j.ijpharm.2006.07.016 10.1039/C5CC08216A 10.3390/cryst9120649 10.1007/s10953-009-9373-8 10.1002/ijc.25864 10.1039/D0CE00409J 10.1021/jm00129a030 10.1002/jps.2600590523 10.1517/13543784.2015.1070483 10.1517/17425247.2013.747508 10.1016/j.jddst.2019.101462 10.1039/C8CE00689J 10.1016/j.ijpharm.2012.10.043 10.1007/s11095-012-0709-5 10.1038/bjc.2012.153 |
ContentType | Journal Article |
Copyright | Copyright Royal Society of Chemistry 2021 |
Copyright_xml | – notice: Copyright Royal Society of Chemistry 2021 |
DBID | AAYXX CITATION 7U5 8FD L7M |
DOI | 10.1039/d0ce01341b |
DatabaseName | CrossRef Solid State and Superconductivity Abstracts Technology Research Database Advanced Technologies Database with Aerospace |
DatabaseTitle | CrossRef Technology Research Database Advanced Technologies Database with Aerospace Solid State and Superconductivity Abstracts |
DatabaseTitleList | CrossRef Technology Research Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1466-8033 |
EndPage | 662 |
ExternalDocumentID | 10_1039_D0CE01341B d0ce01341b |
GroupedDBID | 0-7 0R 1TJ 29F 5GY 70 705 70J 7~J AAEMU AAGNR AAIWI AANOJ AAPBV ABDVN ABGFH ABPTK ABRYZ ACGFS ACLDK ADACO ADMRA ADSRN AENEX AFVBQ AGKEF AGSTE AGSWI ALMA_UNASSIGNED_HOLDINGS ASKNT AUDPV AZFZN BLAPV BSQNT C6K CKLOX CS3 E3Z EBS ECGLT EE0 EF- GNO HZ H~N IDZ J3I JG KC5 N9A O9- OK1 P2P R7B RCNCU RIG RNS RPMJG RRA RRC RSCEA SKA SLH VH6 0R~ 6J9 70~ AAJAE AAMEH AAWGC AAXHV AAXPP AAYXX ABASK ABEMK ABJNI ABPDG ABXOH ACGFO AEFDR AENGV AESAV AETIL AFLYV AFOGI AFRZK AGEGJ AGRSR AHGCF AKMSF ANUXI APEMP CITATION GGIMP H13 HZ~ R56 RAOCF 7U5 8FD L7M |
ID | FETCH-LOGICAL-c233t-202a8b10414c41259a91808eed5aaf36699c800cdc35e1af0b3d4a85304423513 |
ISSN | 1466-8033 |
IngestDate | Mon Jun 30 05:15:56 EDT 2025 Tue Jul 01 02:07:19 EDT 2025 Thu Apr 24 22:58:39 EDT 2025 Sat Jan 08 03:52:05 EST 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c233t-202a8b10414c41259a91808eed5aaf36699c800cdc35e1af0b3d4a85304423513 |
Notes | Electronic supplementary information (ESI) available. CCDC For ESI and crystallographic data in CIF or other electronic format see DOI 2026456 10.1039/d0ce01341b ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
ORCID | 0000-0002-8605-6173 0000-0002-6087-4880 0000-0002-3959-901X |
PQID | 2480290081 |
PQPubID | 2047491 |
PageCount | 1 |
ParticipantIDs | proquest_journals_2480290081 crossref_primary_10_1039_D0CE01341B crossref_citationtrail_10_1039_D0CE01341B rsc_primary_d0ce01341b |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210125 |
PublicationDateYYYYMMDD | 2021-01-25 |
PublicationDate_xml | – month: 1 year: 2021 text: 20210125 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | Cambridge |
PublicationPlace_xml | – name: Cambridge |
PublicationTitle | CrystEngComm |
PublicationYear | 2021 |
Publisher | Royal Society of Chemistry |
Publisher_xml | – name: Royal Society of Chemistry |
References | Phan (D0CE01341B-(cit22)/*[position()=1]) 2019; 9 Thakur (D0CE01341B-(cit30)/*[position()=1]) 2009; 38 Tao (D0CE01341B-(cit33)/*[position()=1]) 2019; 19 Luo (D0CE01341B-(cit16)/*[position()=1]) 2018; 20 Sun (D0CE01341B-(cit40)/*[position()=1]) 2008; 8 Dai (D0CE01341B-(cit13)/*[position()=1]) 2020; 22 Shimpi (D0CE01341B-(cit21)/*[position()=1]) 2018; 18 Praphanwittaya (D0CE01341B-(cit9)/*[position()=1]) 2020; 55 Hu (D0CE01341B-(cit10)/*[position()=1]) 2017; 153 Eisenberg (D0CE01341B-(cit24)/*[position()=1]) 1962; 8 Wang (D0CE01341B-(cit14)/*[position()=1]) 2018; 20 Sun (D0CE01341B-(cit12)/*[position()=1]) 2013; 10 Das (D0CE01341B-(cit31)/*[position()=1]) 2007; 48 Dai (D0CE01341B-(cit37)/*[position()=1]) 2020; 20 Lin (D0CE01341B-(cit39)/*[position()=1]) 2016; 85 Sun (D0CE01341B-(cit26)/*[position()=1]) 2016; 72 Wilhelm (D0CE01341B-(cit1)/*[position()=1]) 2011; 129 Shiraishi (D0CE01341B-(cit25)/*[position()=1]) 1989; 32 Chow (D0CE01341B-(cit42)/*[position()=1]) 2012; 29 Abd El-Wahed (D0CE01341B-(cit32)/*[position()=1]) 2008; 888 Mross (D0CE01341B-(cit4)/*[position()=1]) 2012; 18 Thakuria (D0CE01341B-(cit19)/*[position()=1]) 2013; 453 Sun (D0CE01341B-(cit41)/*[position()=1]) 2006; 326 Sun (D0CE01341B-(cit17)/*[position()=1]) 2004; 21 Duggirala (D0CE01341B-(cit11)/*[position()=1]) 2016; 52 Lee (D0CE01341B-(cit2)/*[position()=1]) 2015; 24 Alfons (D0CE01341B-(cit6)/*[position()=1]) 2007 Pavlicic (D0CE01341B-(cit29)/*[position()=1]) 2002; 7 Juergen (D0CE01341B-(cit8)/*[position()=1]) 2007 Pinto (D0CE01341B-(cit28)/*[position()=1]) 2007; 50 Kale (D0CE01341B-(cit20)/*[position()=1]) 2020; 12 Sanphui (D0CE01341B-(cit18)/*[position()=1]) 2015; 12 Jr (D0CE01341B-(cit3)/*[position()=1]) 2014; 79 Surov (D0CE01341B-(cit15)/*[position()=1]) 2014; 11 Strumberg (D0CE01341B-(cit5)/*[position()=1]) 2012; 106 Fell (D0CE01341B-(cit27)/*[position()=1]) 1970; 59 |
References_xml | – issn: 2007 volume-title: Polymorph III of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide doi: Alfons Juergen Katharina Birgit – issn: 2007 volume-title: Polymorph II of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide doi: Juergen Alfons Katharina Birgit – issn: 2007 volume-title: 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate doi: Alfons Juergen Katharina Birgit – volume: 18 start-page: 4378 year: 2018 ident: D0CE01341B-(cit21)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/acs.cgd.8b00362 – volume: 8 start-page: 437 year: 1962 ident: D0CE01341B-(cit24)/*[position()=1] publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/0006-291X(62)90292-9 – volume: 12 start-page: 1615 year: 2015 ident: D0CE01341B-(cit18)/*[position()=1] publication-title: Mol. Pharmaceutics doi: 10.1021/acs.molpharmaceut.5b00020 – volume: 79 start-page: 34 year: 2014 ident: D0CE01341B-(cit3)/*[position()=1] publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2013.11.002 – volume: 11 start-page: 3707 year: 2014 ident: D0CE01341B-(cit15)/*[position()=1] publication-title: Mol. Pharmaceutics doi: 10.1021/mp5004652 – volume: 12 start-page: 156 year: 2020 ident: D0CE01341B-(cit20)/*[position()=1] publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12060546 – volume: 72 start-page: 291 year: 2016 ident: D0CE01341B-(cit26)/*[position()=1] publication-title: Acta Crystallogr., Sect. C: Struct. Chem. doi: 10.1107/S2053229616003727 – volume: 888 start-page: 416 year: 2008 ident: D0CE01341B-(cit32)/*[position()=1] publication-title: J. Mol. Struct. doi: 10.1016/j.molstruc.2008.01.009 – volume: 85 start-page: 141 year: 2016 ident: D0CE01341B-(cit39)/*[position()=1] publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2015.10.006 – year: 2007 ident: D0CE01341B-(cit8)/*[position()=1] – volume: 8 start-page: 1575 year: 2008 ident: D0CE01341B-(cit40)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/cg700843s – volume: 19 start-page: 5636 year: 2019 ident: D0CE01341B-(cit33)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/acs.cgd.9b00618 – volume: 18 start-page: 2658 year: 2012 ident: D0CE01341B-(cit4)/*[position()=1] publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1900 – volume: 153 start-page: 61 year: 2017 ident: D0CE01341B-(cit10)/*[position()=1] publication-title: Colloids Surf., B doi: 10.1016/j.colsurfb.2017.02.006 – volume: 20 start-page: 3025 year: 2018 ident: D0CE01341B-(cit16)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/C8CE00341F – volume: 7 start-page: 871 year: 2002 ident: D0CE01341B-(cit29)/*[position()=1] publication-title: Molecules doi: 10.3390/71200871 – volume: 48 start-page: 381 year: 2007 ident: D0CE01341B-(cit31)/*[position()=1] publication-title: Kinet. Catal. doi: 10.1134/S0023158407030068 – volume: 20 start-page: 5160 year: 2020 ident: D0CE01341B-(cit37)/*[position()=1] publication-title: Cryst. Growth Des. doi: 10.1021/acs.cgd.0c00326 – volume: 21 start-page: 382 year: 2004 ident: D0CE01341B-(cit17)/*[position()=1] publication-title: Pharm. Res. doi: 10.1023/B:PHAM.0000016272.81390.b4 – volume: 50 start-page: 5339 year: 2007 ident: D0CE01341B-(cit28)/*[position()=1] publication-title: J. Med. Chem. doi: 10.1021/jm070245n – volume: 326 start-page: 94 year: 2006 ident: D0CE01341B-(cit41)/*[position()=1] publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2006.07.016 – volume: 52 start-page: 640 year: 2016 ident: D0CE01341B-(cit11)/*[position()=1] publication-title: Chem. Commun. doi: 10.1039/C5CC08216A – volume: 9 start-page: 649 year: 2019 ident: D0CE01341B-(cit22)/*[position()=1] publication-title: Crystals doi: 10.3390/cryst9120649 – volume: 38 start-page: 265 year: 2009 ident: D0CE01341B-(cit30)/*[position()=1] publication-title: J. Solution Chem. doi: 10.1007/s10953-009-9373-8 – volume: 129 start-page: 245 year: 2011 ident: D0CE01341B-(cit1)/*[position()=1] publication-title: Int. J. Cancer doi: 10.1002/ijc.25864 – volume: 22 start-page: 3670 year: 2020 ident: D0CE01341B-(cit13)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/D0CE00409J – volume: 32 start-page: 2214 year: 1989 ident: D0CE01341B-(cit25)/*[position()=1] publication-title: J. Med. Chem. doi: 10.1021/jm00129a030 – year: 2007 ident: D0CE01341B-(cit6)/*[position()=1] – volume: 59 start-page: 688 year: 1970 ident: D0CE01341B-(cit27)/*[position()=1] publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600590523 – volume: 24 start-page: 1307 year: 2015 ident: D0CE01341B-(cit2)/*[position()=1] publication-title: Expert Opin. Invest. Drugs doi: 10.1517/13543784.2015.1070483 – volume: 10 start-page: 201 year: 2013 ident: D0CE01341B-(cit12)/*[position()=1] publication-title: Expert Opin. Drug Delivery doi: 10.1517/17425247.2013.747508 – volume: 55 start-page: 101462 year: 2020 ident: D0CE01341B-(cit9)/*[position()=1] publication-title: J. Drug Delivery Sci. Technol. doi: 10.1016/j.jddst.2019.101462 – volume: 20 start-page: 5945 year: 2018 ident: D0CE01341B-(cit14)/*[position()=1] publication-title: CrystEngComm doi: 10.1039/C8CE00689J – volume: 453 start-page: 101 year: 2013 ident: D0CE01341B-(cit19)/*[position()=1] publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2012.10.043 – volume: 29 start-page: 1854 year: 2012 ident: D0CE01341B-(cit42)/*[position()=1] publication-title: Pharm. Res. doi: 10.1007/s11095-012-0709-5 – volume: 106 start-page: 1722 year: 2012 ident: D0CE01341B-(cit5)/*[position()=1] publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.153 |
SSID | ssj0014110 |
Score | 2.3890772 |
Snippet | Regorafenib (REG) is an oral multikinase inhibitor used for the treatment of gastrointestinal stromal tumors, metastatic colorectal cancer and advanced... |
SourceID | proquest crossref rsc |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 653 |
SubjectTerms | Bioavailability Cancer Crystallography Dicarboxylic acids Dissolution Dynamic stability Fourier transforms Hygroscopicity Infrared analysis NMR spectroscopy Solubility Thermal analysis |
Title | Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation |
URI | https://www.proquest.com/docview/2480290081 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELXo9gIHxFfF0oIswQWBwYmdbMKtpKlKFcolK-0tchynREJJtbuVuvx6xrETB6gQcIlW2XxInpfxG3vmDUKvQn8BrGEhyKLW24whlwRIbEyYimquIvi373X4-SI8W_LzVbByaUV9dcm2fCe_31pX8j9WhXNgV10l-w-WHR8KJ-A32BeOYGE4_pWNk06ud0DvjAJyX20iatU2pVle1Vsw67K72WkhayGbqk9_2-xaIH0boy0gR71mU45pdQO6Ky25O5ECn3LYRL8zbS91bcmYgHPdkmzI7m1GV79qBMmMSsGJaJy368h5o94kX13irWovSW77q2TNdC3C1wsRxNQt2yQmveIxpJv26SS2aZ2ZbYyL5aGWQDbyF4MPNjXHFmts4lBDIyVs5-bQeO7f3D5lWjW1olJRLVBXuslt2NC_-FKcLrOsyNNVvof2fQgq_BnaP07zT9m468SBCw0Stix-7573M2lxkcjeemgT09OR_AG6b-MIfGxA8RDdUe0jdG-iLvkY1Q4euKvxBB5YwwNP4YF7eHzAIzje4l-hgQEaeIAGdtB4gpanaZ6cEdtWg0ifsS18Qb6ISgjDPS458NtYxF5EIyBLgRA1C8M4lhBGyEqyQHmipiWruABaRzlw78BjB2jWdq16irAQolJlQP06UFx6LBKKciElp3HEFrKco9fDuBXSas7r1iffij73gcXFCU3Sfow_ztHL8doro7Ry61VHw_AX9kvcFD6PqB9rdjtHB2CS8X5nwWd_vu8Q3XV4PkKz7fpaPQe2uS1fWJD8ABjjhgk |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cocrystals+of+regorafenib+with+dicarboxylic+acids%3A+synthesis%2C+characterization+and+property+evaluation&rft.jtitle=CrystEngComm&rft.au=Jun-Long%2C+Jia&rft.au=Xia-Lin%2C+Dai&rft.au=Hao-Jie+Che&rft.au=Meng-Ting%2C+Li&rft.date=2021-01-25&rft.pub=Royal+Society+of+Chemistry&rft.eissn=1466-8033&rft.volume=23&rft.issue=3&rft.spage=653&rft.epage=662&rft_id=info:doi/10.1039%2Fd0ce01341b&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-8033&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-8033&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-8033&client=summon |